Methods of computed tomography screening and management of lung cancer in Tianjin: design of a population-based cohort study

References

1. 1.↵
   2. Zhou MG,
   3. Wang HD,
   4. Zhu J,
   5. Chen WQ,
   6. Wang LH,
   7. Liu SW, et al.

   Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet. 2016; 387: 251–72.

   OpenUrlCrossRefPubMed
2. 2.↵
   2. Chen WQ,
   3. Zheng RS,
   4. Baade PD,
   5. Zhang SW,
   6. Zeng HM,
   7. Bray F, et al.

   Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66: 115–32.

   OpenUrlCrossRefPubMed
3. 3.↵
   2. Chang S,
   3. Dai M,
   4. Ren JS,
   5. Chen YH,
   6. Guo LW.

   Estimates and prediction on incidence, mortality and prevalence of lung cancer in China in 2008. Chin J Epidemiol. 2012; 33: 391–4.

   OpenUrl
4. 4.↵
   2. Ferlay J,
   3. Shin HR,
   4. Bray F,
   5. Forman D,
   6. Mathers C,
   7. Parkin DM.

   Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127: 2893–917.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   2. Wang JB,
   3. Fan YG,
   4. Jiang Y,
   5. Li P,
   6. Xiao HJ,
   7. Chen WQ, et al.

   Attributable causes of lung cancer incidence and mortality in China. Thorac Cancer. 2011; 2: 156–63.

   OpenUrl
6. 6.↵
   Chinese Center for Disease Control and Prevention. 2015 China Adult Tobacco Survey Report (in Chinese)., Available from: http://www.chinacdc.cn/gwswxx/kyb/201512/t20151228_123960.html. [Accessed December 21, 2018].
7. 7.↵
   2. Chen WQ,
   3. Zheng RS,
   4. Zeng HM,
   5. Zhang SW.

   Epidemiology of lung cancer in China. Thorac Cancer. 2015; 6: 209–15.

   OpenUrl
8. 8.↵
   2. Shao Q,
   3. Li JB,
   4. Li FX,
   5. Wang SZ,
   6. Wang W,
   7. Liu SS, et al.

   Clinical investigation into the initial diagnosis and treatment of 1, 168 lung cancer patients. Oncol Lett. 2015; 9: 563–8.

   OpenUrlPubMed
9. 9.↵
   2. Wei SH,
   3. Tian JT,
   4. Song XP,
   5. Wu BQ,
   6. Liu LM.

   Causes of death and competing risk analysis of the associated factors for non-small cell lung cancer using the Surveillance, Epidemiology, and End Results database. J Cancer Res Clin Oncol. 2018; 144: 145–55.

   OpenUrl
10. 10.↵
    2. Yang P,
    3. Allen MS,
    4. Aubry MC,
    5. Wampfler JA,
    6. Marks RS,
    7. Edell ES, et al.

    Clinical features of 5, 628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005; 128: 452–62.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    2. Oudkerk M,
    3. Devaraj A,
    4. Vliegenthart R,
    5. Henzler T,
    6. Prosch H,
    7. Heussel CP, et al.

    European position statement on lung cancer screening. Lancet Oncol. 2017; 18: e754–66.
12. 12.↵
    National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365: 395–409.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    2. Horeweg N,
    3. van Rosmalen J,
    4. Heuvelmans MA,
    5. van der Aalst CM,
    6. Vliegenthart R,
    7. Scholten ET, et al.

    Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet Oncol. 2014; 15: 1332–41.

    OpenUrlCrossRefPubMed
14. 14.
    2. Walter JE,
    3. Heuvelmans MA,
    4. de Jong PA,
    5. Vliegenthart R,
    6. van Ooijen PMA,
    7. Peters RB, et al.

    Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial. Lancet Oncol. 2016; 17: 907–16.

    OpenUrlCrossRefPubMed
15. 15.↵
    2. Wang ZX,
    3. Han W,
    4. Zhang WW,
    5. Xue F,
    6. Wang YY,
    7. Hu YD, et al.

    Mortality outcomes of low-dose computed tomography screening for lung cancer in urban China: a decision analysis and implications for practice. Chin J Cancer. 2017; 36: 57.

    OpenUrl
16. 16.↵
    NCCN Clinical Practice Guidelines in Oncology: Lung Cancer Screening (version 2. 2018). Available from: https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/lung_screening.pdf. [Accessed December 21, 2018].
17. 17.
    2. MacMahon H,
    3. Austin JHM,
    4. Gamsu G,
    5. Herold CJ,
    6. Jett JR,
    7. Naidich DP, et al.

    Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology. 2005; 237: 395–400.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    2. Zhou QH,
    3. Fan YG,
    4. Bu H,
    5. Wang Y,
    6. Wu N,
    7. Huang YC, et al.

    China national lung cancer screening guideline with low-dose computed tomography (2015 version). Thorac Cancer. 2015; 6: 812–8.

    OpenUrl
19. 19.↵
    2. van Klaveren RJ,
    3. Oudkerk M,
    4. Prokop M,
    5. Scholten ET,
    6. Nackaerts K,
    7. Vernhout R, et al.

    Management of lung nodules detected by volume CT scanning. N Engl J Med. 2009; 361: 2221–9.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    2. Field JK,
    3. Marcus MW,
    4. Oudkerk M.

    Risk assessment in relation to the detection of small pulmonary nodules. Transl Lung Cancer Res. 2017; 6: 35–41.

    OpenUrl
21. 21.↵
    Important grant for collaboration in research on early detection of lung cancer, COPD and cardiovascular diseases. https://www.rug.nl/news/2016/11/grote-subsidie-voor-samenwerking-in-onderzoek-vroege-opsporing-longkanker_-copd-en-hart--en-vaatziekten?lang=en. [Accessed December 21, 2018]
22. 22.↵
    2. Kakinuma R,
    3. Noguchi M,
    4. Ashizawa K,
    5. Kuriyama K,
    6. Maeshima AM,
    7. Koizumi N, et al.

    Natural history of pulmonary subsolid nodules: a prospective multicenter study. J Thorac Oncol. 2016; 11: 1012–28.

    OpenUrl
23. 23.↵
    2. Liu YA,
    3. Sun H,
    4. Zhou F,
    5. Su CX,
    6. Gao GH,
    7. Ren SX, et al.

    Imaging features of TSCT predict the classification of pulmonary preinvasive lesion, minimally and invasive adenocarcinoma presented as ground glass nodules. Lung Cancer. 2017; 108: 192–7.

    OpenUrl
24. 24.↵
    2. Song YS,
    3. Park CM,
    4. Park SJ,
    5. Lee SM,
    6. Jeon YK,
    7. Goo JM.

    Volume and mass doubling times of persistent pulmonary subsolid nodules detected in patients without known malignancy. Radiology. 2014; 273: 276–84.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    EQ-5D. Available from: https://euroqol.org/eq-5d-instruments/eq-5d-3l-available-modes-of-administration/ [Accessed December 21, 2018].
26. 26.↵
    2. Liu GG,
    3. Wu HY,
    4. Li MH,
    5. Gao C,
    6. Luo N.

    Chinese time trade-off values for EQ-5D health states. Value Health. 2014; 17: 597–604.

    OpenUrlCrossRefPubMed
27. 27.↵
    Cardiothoracic Group of Radiology Branch in Chinese Medical Association. Chinese expert consensus on the Low-dose spiral CT lung cancer screening (in Chinese). Chin J Radiol. 2015; 49: 328-35.

    OpenUrl
28. 28.↵
    2. Bach PB,
    3. Mirkin JN,
    4. Oliver TK,
    5. Azzoli CG,
    6. Berry D,
    7. Brawley OW, et al.

    Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012; 307: 2418–29.

    OpenUrlCrossRefPubMedWeb of Science
29. 29.↵
    The State Council, The People’s Republic of China. The general office of the CPC Central Committee and the general office of the State Council issued the opinions on deepening the reform of the examination and approval system and encouraging the innovation of pharmaceutical and medical devices (in Chinese)., Available from: http://www.gov.cn/xinwen/2017-10/08/content_5230105.htm[Accessed December 21, 2018].